Sunovion gains Elevation in respiratory sector with promising nebulised COPD contender
This article was originally published in Scrip
Dainippon Sumitomo Pharma's Sunovion Pharmaceuticals unit will pay $100 million upfront and up to $330 million in milestone payments to acquire Elevation Pharmaceuticals, based on positive Phase IIb data in moderate to severe chronic obstructive pulmonary disease (COPD) for the private San Diego-based company's nebulised long-acting muscarinic antagonist (LAMA) EP-101.
You may also be interested in...
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.